Lysaker, 20 April 2015
In accordance with the authorization granted by the Annual General Meeting 13th May 2014, the Board of Directors of PCI Biotech Holding ASA has awarded a total of 93,500 options to key employees. Each option gives the right to subscribe for or acquire one share per option (after PCI Biotech Holding ASA's choice), at a strike price of NOK 12.53, equal to the volume weighted average price (VWAP) for the last 5 days of trade prior to the grant date. The options can be exercised with 1/3 of the options after one year, further 1/3 after two years and the last third after three years. The options are lapsing in Q3 2020.
Of these options, 20,000 options were allotted to Ronny Skuggedal, CFO. After the allocation, Ronny Skuggedal holds a total portfolio of 60,000 unexercised options and 0 shares.
For more information, please contact:
Per Walday, CEO
E-mail: pw@pcibiotech.no
Mobile: 917 93 429